Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer – nejm.org
Business News
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer nejm.org
- ESMO: AstraZeneca, Merck’s Lynparza boosts prostate cancer survival by 31% over J&J, Pfizer-Astellas rivals FiercePharma
- Breast cancer drug set to transform prostate cancer treatment Medical Xpress
- Genetic drug olaparib heralds ‘new era’ for prostate cancer treatment The Times
- View Full Coverage on Google News
Source: Business News